Wireless Eye Implant Restores Partial Vision to People with Macular Degeneration

For people with advanced vision loss, losing the ability to read is often one of the hardest changes to accept. Everyday tasks – such as checking a phone number, reading a label, or recognizing a short word – can suddenly turn into impossible. Now, researchers have shown that a tiny wireless eye implant may aid restore some of that lost central vision.

Patients Gain Back Vision

In a clinical study, many older adults who are blind due to advanced macular degeneration regained enough clarity to recognize letters and short words. Whereas the device does not restore natural sight, it helped several participants read again after years of irreversible vision decline. After one year, participants gained an average of 25 letters on a standard eye chart, roughly equal to five lines of vision. Meaningful improvements were observed in 26 of the 32 participants who completed follow-up testing, according to Dr. Jose-Alain Sahel at the University of Pittsburgh.

Twenty-seven participants used the artificial central vision at home, reading numbers or short words in daily life. Still, the restored vision remained limited, focusing only on central detail and working only when the implant system was active. It cannot fully replace natural sight.

How the PRIMA Implant Works

The device targets age-related macular degeneration, an eye disease that damages the center of the retina. In this condition, photoreceptors – light-sensing cells that convert light into nerve signals – gradually die off. When these cells disappear, the brain stops receiving clear information from the center of the visual field. In a late stage called geographic atrophy, large patches of these cells die completely, resulting in a permanent blank spot in the center of vision.

The PRIMA implant, about 2 millimeters wide, sits beneath the retina where photoreceptors once existed. It attempts to solve the problem by replacing the lost light sensors with a tiny electronic chip. Each tiny pixel acts like a photovoltaic cell, using light to generate electricity. These electrical signals stimulate nearby retinal neurons, which then send visual information through the optic nerve to the brain.

The implant does not work alone. Participants wear specialized glasses that capture and project images to the chip. A modest camera on the glasses records what the wearer sees, and that image is transmitted to the implant using near-infrared light, allowing the system to operate wirelessly inside the eye. Users can adjust zoom and contrast settings on the glasses to improve readability.

Surgical Procedure and Safety

Implanting the chip requires delicate retinal surgery. Surgeons place the device beneath the retina and position it precisely inside the damaged central region. In safety data from the PRIMAvera clinical trial, 26 serious adverse events occurred in 19 participants, most within the first two months after surgery. Approximately 81 percent of complications appeared within the first two months, and 95 percent resolved within two months of treatment. Researchers believe most of the issues were related to the surgical procedure rather than the implant itself.

Learning to See Again and Limitations

Even after the implant is activated, vision does not immediately feel natural. Participants worked with rehabilitation teams to learn how to interpret the new signals. Practice sessions helped patients connect head movements and light patterns with shapes, lines, and eventually letters. Peripheral vision usually remained unchanged after surgery, so patients relied on their natural side vision to locate objects, while the implant provided central detail.

Even with improvement, the restored visual field remained narrow. Users often had to move their head to scan across text or objects. For now, the technology cannot restore abilities such as face recognition or driving. Its main benefit is helping patients perform specific tasks like reading numbers or short words.

Future Steps and Regulatory Approval

The device was tested in the PRIMAvera clinical trial, which implanted 38 volunteers age 60 and older across 17 hospitals in five European countries. Science Corporation has submitted an application for CE mark approval in Europe, which would allow the device to be used clinically. In the United States, the company is discussing possible approval pathways with the U.S. Food and Drug Administration (FDA).

Future studies will need to track whether the visual signal remains stable for years and how continuing retinal degeneration might affect performance. Even if the device receives approval, access may depend on surgical capacity, specialized training, and rehabilitation programs.

The results suggest that replacing dead photoreceptors with a light-powered chip could one day restore useful central vision for many people living with severe retinal disease.

The study was published in the New England Journal of Medicine.